All News
Zuo @jasonsknight et al. Dallas Heart Study. aPL and incident CV events. IgA isotypes of aCLand aβ2GPI were independently associated with future ASCVD events. @rheumnow #ACR22 Abstr#0681 https://t.co/C7O4rnFZCG https://t.co/1H7uiPUwuv
Richard Conway RichardPAConway ( View Tweet)
Abs 0674 finds that HIT is rare among hospitalized APS and SLE patients with aPL and that anti-PF4 antibodies are often inappropriately tested in this population. #ACR22 @RheumNow https://t.co/hFZzpuEkDG https://t.co/hyUYVZLUM4
Dr. Rachel Tate uptoTate ( View Tweet)
🔥 VEXAS + the 🫁 🔥
🔑 Points ~
🫁 involvement common
👉cough + dyspnea
🌬PFTS often normal
🩻 CXR useful but HRCT superior
🩻ground glass opacity commonest finding
💊 good response GC
🔥ignite session🔥
#ACR22
Abst# 1569 @RheumNow
Patricia Harkins DrTrishHarkins ( View Tweet)
Abs 0345 finds association between cumulated HCQ and development of cardiac abnormalities. We need further data to determine clinical association. #ACR22 @RheumNow https://t.co/WmixbFIlfd https://t.co/2Ejwkeu1Az
Dr. Rachel Tate uptoTate ( View Tweet)
In the absence of other high risk factor for thrombosis, Thrombocytopenia (ITP) could be an independent and long-lasting clinical phenotype for aPLs carriers. Abs 0672 #ACR22 @RheumNow https://t.co/LmlruGqkEJ https://t.co/MaIHS0QWN0
Dr. Rachel Tate uptoTate ( View Tweet)
Sometimes we guess how RA pts will be, before they come in.
machine learning to predict RA dx activity:
RISE registry (n=39,155)
inputs: prev CDAI, demo, smoking/obesity, SES
v good performance
Past performance does predict future outcomes, sometimes!
ABST0905 #ACR22 @RheumNow https://t.co/Ir1YG1cqlD
David Liew drdavidliew ( View Tweet)
Kajiyama et al. JAKi counteract cellular toxicity of HCQ in vitro. Could they prevent HCQ-retinopathy? @rheumnow #ACR22 Abstr#0653 https://t.co/c0a4OYCzw5 https://t.co/X7pFM7j1R4
Richard Conway RichardPAConway ( View Tweet)
RheumNow’s expanded coverage of the #ACR22 meeting is sponsored in part by Bristol-Myers Squibb. All content chosen by RheumNow & its Faculty
Dr. John Cush RheumNow ( View Tweet)
Park et al. Risk-benefit of PJP propylaxis in rituximab treated patients. NNH 86 . NNT - all RTX 146, RTX+high dose steroid 21. This mirrors my practice @RheumNow #ACR22 Abstr#0720 https://t.co/JPtPCqah9R https://t.co/bonRzWFbVw
Richard Conway RichardPAConway ( View Tweet)
Kaneko et al. Tocilizumab leads to significantly lower steroid doses in Adult onset Stills Disease @RheumNow #ACR22 Abstr#0826 https://t.co/jc1S6sdfkm https://t.co/z0cHB4wYu6
Richard Conway RichardPAConway ( View Tweet)
What neonatal factors could affect development into axSpA? Turns out antibiotic exposure (6.2x more likely).
Mode of delivery, early diet (milk vs. formula), maternal smoking (!!) did not show association.
@RheumNow #ACR22 Abs#0868
#ACRBest https://t.co/roCAj5YsCt
Robert B Chao, MD doctorRBC ( View Tweet)
In non-renal SLE, BEL associated w/ a lower risk of severe infection and hospitalizations due to severe infection compared to MTX, AZA, MMF. Abs 0349 #ACR22 @RheumNow https://t.co/0EBpCMPOqF https://t.co/vdxKVJSaZA
Dr. Rachel Tate uptoTate ( View Tweet)
Isenberg et al. Atacicept 150mg in SLE. Reduced flare 36% vs 53%, delayed time to first flare, stabalised renal function (vs decline in PBO), less steroid increase (14% vs 36%), UPCR declined (vs increase in PBO) @RheumNow #ACR22 Abstr#1001 https://t.co/FRWcTAgCrn https://t.co/Amkg84OX2x
Richard Conway RichardPAConway ( View Tweet)
🔥Ignite Talk 10:20AM South Philly Stage🔥 abstract #0946
SLE, birth control, & pregnancy planning
🔥30% of women used no birth control despite only 17% voicing interest in pregnancy
🔥More 1/2 of women interested in pregnancy were not medically ready
#ACR22 @RheumNow
Catherine Sims, MD DrCassySims ( View Tweet)
Vilas-Boas et al. Anti-NOR antibodies. 27.5% of anti-NOR+ diagnosed with rheumatic disease - SSc and UCTD most common. @RheumNow #ACR22 Abstr#0832 https://t.co/OU2hFn3ioK https://t.co/Ve0Jbexycm
Richard Conway RichardPAConway ( View Tweet)
Kahlenberg @Kahlenberglab et al. TYK2i deucravacitinib in SLE. Clinical efficacy (figure). Deucravacitinib suppressed IFN production, IFN-responsive gene expression, IFN-inducible proteins, B cell markers,serological biomarkers. @RheumNow #ACR22 Abstr#1000 https://t.co/zzkoPLOlSR https://t.co/znyG8N5pJ2
Richard Conway RichardPAConway ( View Tweet)
Johnson et al TYK2i deucravacitinib does not inhibit haematologic pathways, Treg function, or IL-15 dependent NK cell function, that JAKi do. @rheumnow #ACR22 Abstr#0584 https://t.co/UTHzUjGmJN https://t.co/NUKKAv3tAr
Richard Conway RichardPAConway ( View Tweet)
Severe non-adherence to HCQ independently assoc'd w/ risk of SLE flare in the following year, with early damage, and 5-year mortality. Abs 0343 #ACR22 @RheumNow https://t.co/JYRWD5QIlf https://t.co/UCWYrHIc4b
Dr. Rachel Tate uptoTate ( View Tweet)
Gopal et al. Withdrawal of immunosuppressants non-inferior to steroid withdrawal in SLE in clinical remission. Numerically higher flare rate in steroid withdrawal group 15 vs 7 (RR 2.1). @RheumNow #ACR22 Abstr#0997 https://t.co/psoHvg0pVG https://t.co/GlsDjpgXGo
Richard Conway RichardPAConway ( View Tweet)
Giblon et al. Incidence depression and anxiety in RA over 30 years. No change in depression, significant increase in anxiety @RheumNow #ACR22 Abstr#0886 https://t.co/1a3sayBEnl https://t.co/jflc3UTbIh
Richard Conway RichardPAConway ( View Tweet)